Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen (NASDAQ: AMGN).

With no new safety signals emerging in its phase 3 trials, Alumis plans to file for FDA approval in the back half of 2026.

Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...

Pharmaceutical giants are not simply lining up behind President Donald Trump's drug agenda, they are trying to bend it. The ...

The thermal management of high-density computing environments represents one of the most consequential engineering challenges ...

We read with interest the article by Santacroce about personalised medicine in eosinophilic oesophagitis (EoE) and the identification of novel therapeutic targets.1 While dietary approaches are ...

Matt Korda, the associate director of the Nuclear Information Project at the Federation of American Scientists, assisted USA ...

M+C Saatchi North America is turning to a longtime pharma pro to serve as its inaugural medical advisor. | M+C Saatchi North ...

HHS’s move Monday to overhaul the childhood vaccine schedule without public input marks Health Secretary Robert F. Kennedy Jr ...

The Air Force's next-generation nuclear missile program has blown its budget and hit serious delays. Here's how things went sideways.

An early proof-of-concept demo of Meta's neural gesture band connected to Garmin's smart car interface is the company's next ...

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.